Clinical Trial Evaluating DC/AML Fusion Cell Vaccination Alone and in Conjunction with PD-1 Blockade in AML Patients Who Achieve a Chemotherapy-Induced Remission
Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), Vicki Held(Rambam Health Care Campus), Poorvi Somaiya(Beth Israel Deaconess Medical Center), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Jon Arnason(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Lowell T. Nicholson(Dana-Farber Cancer Institute), Jessica Bonhoff(Beth Israel Deaconess Medical Center), Natalie Drummy(Beth Israel Deaconess Medical Center), Lynne Uhl(Hadassah Medical Center), Carol Delaney(Beth Israel Deaconess Medical Center), Ilene Galinsky(Dana-Farber Cancer Institute), Katarina Luptakova(Tesaro (United States)), Donald Küfe(Dana-Farber Cancer Institute), Jacob M. Rowe(Technion – Israel Institute of Technology), Richard M. Stone(Dana-Farber Cancer Institute), Yan Emily Yuan(Beth Israel Deaconess Medical Center), Baldev Vasir(Beth Israel Deaconess Medical Center), Dimitrios Tzachanis(Dana-Farber Cancer Institute), Irit Avivi(Tel Aviv Sourasky Medical Center), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Lina Bisharat(Beth Israel Deaconess Medical Center), David P. Steensma(Harvard University), Dina Stroopinsky(Beth Israel Deaconess Medical Center), Tami Katz(Beth Israel Deaconess Medical Center), Heidi Mills(Beth Israel Deaconess Medical Center), Donna Neuberg(Otsuka (Japan)), James D. Levine(Beth Israel Deaconess Medical Center), Jeffrey I. Zwicker(Memorial Sloan Kettering Cancer Center)
Cited by 3
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k